GT90008 / Kintor Pharma, Suzhou Zelgen - LARVOL DELTA

Kintor Pharma Announces 2021 Business Progress and Annual Results (PRNewswire) - "Expected Milestones: (i) Kintor Pharma expects to dose the first patient of ALK-1 antibody's phase II clinical trial combined with nivolumab for the second-line treatment for advanced HCC in the US in H1 2022; (ii) Kintor Pharma expects to dose the first patient of GT90008's phase I clinical trial in China in H2 2022."

Trial status • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Kintor Pharma Announces PD-L1/TGF-β dual-targeting antibody (GT90008) Approved for Advanced Solid Tumour Clinical Trial in China (PRNewswire) - "Kintor Pharmaceutical...announced that the clinical trial of PD-L1/TGF-β dual-targeting antibody (GT90008) for the treatment of advanced solid tumours was approved by the National Medical Products Administration (NMPA) of China on 21 October 2021....The rapid progress from in-license to IND approval has demonstrated our team's great execution capability."

New trial • Oncology • Solid Tumor